Corresponding Author: Dr. Anna Louise David, MB ChB, MRCOG, PhD

Corresponding Author's Institution: University College London

First Author: Anna Louise David, MB ChB, MRCOG, PhD

Order of Authors: Anna Louise David, MB ChB, MRCOG, PhD; Eric R Jauniaux,
PhD FRCOG

Abstract: Introduction: To study the relationship between 2-dimensional
placental ultrasound measurements and maternal serum (MS) levels of
biomarkers of placentation and in pregnancies presenting with an isolated
abnormally high or low birthweight at term, without evidence of placental
insufficiency.
Method: We performed a population based cohort study of 306 pregnancies
delivered at term including 30 presenting with large-for-gestational age
(LGA, birthweight > 90th centile) and 17 small-for-gestational age (SGA;
birthweight < 10th centile). Antenatal measurements included placental
thickness and 2D-volume and MS levels of pregnancy-associated plasma
protein A (PAPP-A) and free-beta human chorionic gonadotrophin (fβhCG) at
11 - 13+6 weeks of gestation and mid-trimester MS α-fetoprotein (AFP),
unconjugated estriol (uE3) and inhibin A levels.
Results: In the subgroup with a normal birthweight (10th-90th centile),
there was a significant positive correlation between birthweight and the
basal plate surface area (p<0.001) and 2D placental volume (p< 0.01). In
the LGA subgroup, MS PAPP-A was significantly (p<0.05) higher than in
normal controls and there was a significant (p<0.01) positive correlation
with birthweight. There was no significant difference for any of the
ultrasound and biomarkers parameters between SGA and the normally grown
controls.
Discussion: In uncomplicated singleton pregnancies with a normal
birthweight, 2D measurements of placentation are related with fetal size
but are not related to subsequent excessive or slow fetal growth. LGA at
birth is associated with increased MS PAPP-A at 11-14 weeks of gestation
supporting the association between PAPP-A synthesis and early placental
growth and development.

Dear Graham

As requested, I have added in the Supplementary Figures 1 and 2 (Scatter plot illustrating the relationship between first trimester placental surface area or 2D volume and birthweight for the whole cohort),
Eric has added the statistical data for these results into the results section on page 10. He also corrected 2 typos and added 2 decimals in all the F numbers for consistency.

Yours sincerely
Anna David

Conflict of Interest Statement

The authors state that no conflict of interest exists.

Conflict of Interest Statement

The authors state that no conflict of interest exists.

Ultrasound And Endocrinological Markers Of First Trimester Placentation And Subsequent Fetal Size

A.L. DAVID, E. JAUNIAUX

Research Department of Maternal Fetal Medicine, Institute for Women's Health, University College London, 86-96 Chenies Mews, London WC1E 6HX, UK.

Correspondence address:

Dr Anna David,

Research Department of Maternal Fetal Medicine,

Institute for Women's Health

University College London,

86-96 Chenies Mews,

London WC1E 6HX, UK.

Telephone numbers:

+44/207/6796059

Fax: +44/207/3837429

a.david@ucl.ac.uk

ABSTRACT (243 words)

Introduction: To study the relationship between 2-dimensional placental ultrasound measurements and maternal serum (MS) levels of biomarkers of placentation and in pregnancies presenting with an isolated abnormally high or low birthweight at term, without evidence of placental insufficiency.

Method: We performed a population based cohort study of 306 pregnancies delivered at term including 30 presenting with large-for-gestational age (LGA, birthweight > 90th centile) and 17 small-for-gestational age (SGA; birthweight < 10th centile). Antenatal measurements included placental thickness and 2D-volume and MS levels of pregnancy-associated plasma protein A (PAPP-A) and free-beta human chorionic gonadotrophin (fβhCG) at 11 - 13^{+6} weeks of gestation and mid-trimester MS α-fetoprotein (AFP), unconjugated estriol (uE3) and inhibin A levels.

Results: In the subgroup with a normal birthweight (10th-90th centile), there was a significant positive correlation between birthweight and the basal plate surface area (p<0.001) and 2D placental volume (p< 0.01). In the LGA subgroup, MS PAPP-A was significantly (p<0.05) higher than in normal controls and there was a significant (p<0.01) positive correlation with birthweight. There was no significant difference for any of the ultrasound and biomarkers parameters between SGA and the normally grown controls.

Discussion: In uncomplicated singleton pregnancies with a normal birthweight, 2D measurements of placentation are related with fetal size but are not related to subsequent excessive or slow fetal growth. LGA at birth is

associated with increased MS PAPP-A at 11-14 weeks of gestation supporting the association between PAPP-A synthesis and early placental growth and development.

Highlights

- ~~In a population based cohort study of 306 uncomplicated singleton pregnancies delivered at term, 2D placental measurements correlate with fetal size in the total study group and~~ To study the relationship between 2D placental measurements, maternal placental biomarkers and fetal growth complications

- in ~~uncomplicated singleton~~ pregnancies with a normal birthweight ~~2D placental measurements correlate with fetal size~~

- Placental basal plate surface area and 2D placental volume do not predict large or small fetal size and these measurements cannot be used to predict birthweight in individual cases..

- ~~Large (LGA) and small for gestational age (SGA) at birth are not associated with 2D ultrasound measurements of the placenta~~

- ~~LGA but not SGA is associated with raised first trimester maternal serum pregnancy-associated plasma protein~~ First trimester maternal serum pregnancy-associated plasma protein concentration is higher in LGA pregnancies than compared with normal and AGA pregnancies.

1 # Ultrasound And Endocrinological Markers Of
2 # First Trimester Placentation And Subsequent
3 # Fetal Size

4

5 A.L. DAVID, E. JAUNIAUX

6

7 Research Department of Maternal Fetal Medicine, Institute for Women's
8 Health, University College London, 86-96 Chenies Mews, London WC1E
9 6HX, UK.

10

11

12

13

14 Correspondence address:

15 Dr Anna David,

16 Research Department of Maternal Fetal Medicine,

17 Institute for Women's Health

18 University College London,

19 86-96 Chenies Mews,

20 London WC1E 6HX, UK.

21 Telephone numbers:

22 +44/207/6796059

23 Fax: +44/207/3837429

24 a.david@ucl.ac.uk

25

26

27

ABSTRACT (243 words)

Introduction: To study the relationship between 2-dimensional placental
ultrasound measurements and maternal serum (MS) levels of biomarkers of
placentation and in pregnancies presenting with an isolated abnormally high
or low birthweight at term, without evidence of placental insufficiency.

Method: We performed a population based cohort study of 306 pregnancies
delivered at term including 30 presenting with large-for-gestational age (LGA,
birthweight > 90th centile) and 17 small-for-gestational age (SGA; birthweight
< 10th centile). Antenatal measurements included placental thickness and 2D-
volume and MS levels of pregnancy-associated plasma protein A (PAPP-A)
and free-beta human chorionic gonadotrophin (fβhCG) at 11 - 13^{+6} weeks of
gestation and mid-trimester MS α-fetoprotein (AFP), unconjugated estriol
(uE3) and inhibin A levels.

Results: In the subgroup with a normal birthweight (10th-90th centile), there
was a significant positive correlation between birthweight and the basal plate
surface area (p<0.001) and 2D placental volume (p< 0.01). In the LGA
subgroup, MS PAPP-A was significantly (p<0.05) higher than in normal
controls and there was a significant (p<0.01) positive correlation with
birthweight. There was no significant difference for any of the ultrasound and
biomarkers parameters between SGA and the normally grown controls.

Discussion: In uncomplicated singleton pregnancies with a normal
birthweight, 2D measurements of placentation are related with fetal size but
are not related to subsequent excessive or slow fetal growth. LGA at birth is

51 associated with increased MS PAPP-A at 11-14 weeks of gestation

52 supporting the association between PAPP-A synthesis and early placental

53 growth and development.

54 **Keywords:** Placental volume, birth weight, placental hormones, large for

55 gestational age, small for gestational age

56

1. Introduction

Major changes take place in the uterine environment between the first trimester and the rest of pregnancy [1]. These changes are characterised by the establishment of the intervillous circulation, a switch from histiotrophic to haemotrophic fetal nutrition and the remodelling of the primitive placenta [2]. In early pregnancy, the oxygen concentration within the chorionic sac is maintained at a low value to protect the primitive placenta and the developing fetus from the teratogenic effect of oxygen free radicals [1,2]. The onset of the maternal arterial circulations at the end of the first trimester leads to a three-fold rise in the intraplacental oxygen concentration [1,3]. The haemodynamics of the utero-placental circulation and distribution of oxygen around and inside the placenta play an important role in shaping the topography of the villous tree of the definitive placenta and the formation of the free placental membranes [1-3].

Fetal size is dependent on nutrient availability, which in turn is related to villous development and the capacity of the villous trophoblast to transport these nutrients [4]. Sufficient dilation of the utero-placental circulation together with rapid villous angiogenesis are the key factors necessary for adequate placental development and function, and subsequent fetal growth. Placental and fetal development is related and placental growth kinetics are important features predicting post-natal health and in particular cardiovascular adaptations in childhood, even when fetal size is in the normal range [5]. At birth, there is a correlation between fetal and placental weight and the ratio of these weights i.e. the feto-placental weight ratio (FPR) gives retrospectively

81 an indication of the appropriateness of fetal growth during pregnancy and

82 estimates the potential risks for chronic diseases in later life [6].

83   The placenta actively produces a large number of hormones that serve

84 to regulate and balance maternal and fetal physiology and in particular fetal

85 growth via the production and metabolism of growth-regulating hormones [7].

86 The expression of numerous signaling molecules is altered in the placentas

87 from pregnancies affected by the fetal growth complications of fetal growth

88 restriction and macrosomia. Many maternal serum (MS) biomarkers have

89 been proposed for the detection of abnormal fetal growth but when used

90 alone in the first trimester they have a limited role as screening tests. For

91 example, pregnancy-associated plasma protein-A (PAPP-A) during the first

92 trimester cannot be used alone as a marker of excessive fetal growth, large

93 [8] or of small-for-gestational age (SGA) [9,11]. Similarly new biomarkers such

94 as adiponectin, a hormone that regulates glucose levels and fatty acid

95 oxidation, have been recently tested in the first trimester to predict fetal size

96 later in pregnancy with variable results [12,13].

97   For decades, ultrasound remains the best method for the screening

98 diagnosis, characterization and follow-up of abnormal fetal growth. The

99 advent of Doppler ultrasound has enabled the study of the development of the

100 uterine and umbilical circulations *in utero* from early in normal pregnancy [14].

101 Further studies have shown an association between uterine circulation,

102 abnormal placental features including size, abnormal level of biomarkers in

103 MS and abnormal fetal growth [15,16]. More recently 3-dimensional (3D)

104 ultrasound has enabled the study of placental volume *in utero* throughout

105 pregnancy. These studies have shown an association between placental

106 volume at 11-13 weeks and birth weight in pregnancies with a normal and

107 complicated outcome [17-22].

108   The combination of the assessment of placental size and shape with

109 3D ultrasound and MS biomarkers can serve as the foundation upon which to

110 build a multivariate model for the early prediction of abnormal fetal size. The

111 broad variability in placental volume 3D measurements and current time-

112 consuming approach compared to 2D ultrasound has made its clinical use

113 difficult [23]. In this study, we investigated the relationship between first

114 trimester (11 - 13^{+6} weeks of gestation) 2D ultrasound measurements of

115 placentation and MS levels of commonly measured placental proteins PAPP-

116 A and free-beta human chorionic gonadotrophin (fβhCG), and mid-trimester

117 (15-22^{+0} weeks of gestation) inhibin and subsequent fetal size.

118

119   2. Patients and methods

120 A group of 476 women booked for antenatal care at University College

121 London Hospital (UCLH) were recruited prospectively over a 40-month period.

122 All pregnant women at UCLH are offered a screening test for Trisomy 21

123 which combines nuchal translucency (NT) measurement and MS levels of

124 PAPP-A and fβhCG at 11–13^{+6} weeks (combined test) and/or of AFP, uE3

125 and inhibin-A at 15–22^{+0} weeks (integrated test). All women were recruited at

126 the time of the NT ultrasound examination between 11^{+0} and 13^{+6} weeks of

127 gestation (77-97 gestational days) as determined either by menstrual age, or

6

128   when there was a discrepancy of more than 5 days by the ultrasound

129   measurement of the fetal crown-rump length (CRL).

130   Demographic data including maternal age, ethnicity, parity, cigarette

131   smoke exposure, age and body mass index (BMI) were collected from

132   questionnaires completed at the time of the first appointment. All women

133   underwent routine screening for gestational diabetes with a random glucose

134   at booking and at 28 weeks of gestation. In addition women with specific risk

135   factors (previous LGA, family history of diabetes) were offered a formal 2 hour

136   glucose tolerance test at 28 weeks. Pregnancy outcome information was

137   collected from the medical case notes and hospital electronic patient records.

138   The birthweight percentile was calculated using the customized gestational

139   age related optimal growth chart (GROW) (www.gestation.net), which takes

140   into account ethnicity, maternal height, weight, age and fetal birthweight and

141   gender.

142   Women diagnosed with a first trimester miscarriage, fetal abnormality,

143   medical condition, multiple pregnancy and abnormal pregnancy outcome

144   including, late miscarriage, intrauterine death, stillbirth, preterm (<37 weeks of

145   gestation) or post-term delivery (≥41+6 weeks of gestation), smokers or lost to

146   follow-up were excluded from the analysis. Placental pathology results were

147   available for cases of SGA and IUGR identified at birth.

148   **2.1 Ultrasound examination**

149   All examinations were performed using a 3.5-5 MHz ultrasound probe

150   (Voluson 730 and E8 Expert, GE, USA). In all cases, the fetal NT, CRL and

151   basic anatomy were obtained. The placental basal plate dimensions and

152 thickness were measured by viewing the whole placenta as previously

153 described [25,26]. Three measurements of each parameter were taken and

154 they were subsequently averaged for analysis. In brief the longest sagittal and

155 transverse diameters of the placental basal plate were measured at the level

156 of the utero-placental interface and the placental thickness was measured

157 underneath the cord insertion. The basal plate surface area of the placenta

158 was estimated using the following formula: *Sagittal length x transverse length*

159 *x π/4.* The placental volume was calculated as being the equation for half the

160 volume of an ellipsoid: *½ (sagittal length x transverse length x thickness x*

161 *4/3π), as previously described* [24]. The placental measurements were

162 entered into the prospective study database at the time of the ultrasound

163 scan. Four sonographers were trained by the study authors prior to the study

164 commencement so as to perform the placental ultrasound measurements in a

165 reproducible and systematic way.

166 **2.2 Bioassays**

167 MS PAPP-A and fβhCG levels were measured using the AutoDELFIA PAPP-

168 A, time-resolved fluoro-immunoassay (PerkinElmer, Turku, Finland). Inhibin A

169 MS levels were measured using a commercial ELISA. The measured proteins

170 were converted to multiple of the median (MoM) for a pregnancy of the same

171 gestational age and adjusted for maternal age and ethnicity.

172 **2.3 Study group and statistical analysis**

173   The study group included 306 non-smoking women with a spontaneous

174 singleton pregnancy delivering after an uncomplicated pregnancy between

175 37^{+1} weeks (259 days of pregnancy) and 41^{+6} weeks (286 days of pregnancy).

176 The study group was divided into 3 subgroups according to the neonatal

177 weight percentile at birth adjusted for neonatal gender [24]. Cases in the

178 large-for-gestatonal age (LGA, birth weight > 90th centile) and SGA (birth

179 weight <10th centile with no evidence of fetal growth restriction, as defined as

180 abnormal umbilical artery and uterine artery Doppler or abnormal

181 cerebroplacental ratio) subgroup were individually matched for maternal BMI,

182 parity and for the CRL with three cases from the normal (10-90th centile)

183 subgroup. The study was approved by the Joint UCL/UCLH Committees on

184 the Ethics of Human Research (Reference Number: 05/Q0505/82). All women

185 received information about the study and written consent was obtained prior

186 to the ultrasound examination.

187   The data were analyzed using the StatGraphic data analysis and

188 statistical software package (Station, TX). Standard Kurtosis analysis

189 indicated that some values were not normally distributed and are therefore

190 presented as median and interquartile range (IQR). The median values of the

191 different variable investigated in the macrosomic and SGA subgroups and

192 controls were compared using a Mann-Whitney (Wilcoxon) W test. Individual

193 correlations between the different ultrasound, endocrinologic and clinical

194 variables were calculated by the least square method and their slopes tested

195 for significance by the F ratio test. A p value of <0.05 was considered

196 significant.

197 3. Results

198 There were 259 (84.6%) pregnancies with a birthweight between 10th and 90th

199 centile (normal), 30 (9.8%) with a birthweight >90th centile (LGA) and 17

200 (5.6%) with a birthweight below the 10th centile (SGA).

The regression analysis between birthweight and the ultrasound and endocrinologic parameters in the entire study group indicated a significant positive correlation with placental basal surface area (F= 11.03; r=0.41: P<0.005) and 2D volume (F= 7.60; r=0.29, p<0.01), (Supplementary Figures 1 and 2) and MS PAPP-A concentration (F= 5.10; r=0.14, p<0.05), but no such relationship existed for MS fβhCG.

3.1 Normal birth weight

At the time of the ultrasound examination, the median CRL was 62.3 mm (IQR 56.1;70). Using the NIH BMI calculator (www.nhlbi.nih.gov/ guidelines/obesity/ BMI/ bmicalc.htm), 12 women were classified at the antenatal booking appointment (8-10 weeks of gestation) as underweight (BMI < 18.5), 181 as normal weight (BMI 18.5-24.9), 52 as overweight (BMI 25-29.9 and 14 as obese ($\geq$ 30).

Table 1 displays and compares the clinical, ultrasound and endocrinological data of women with a BMI < 25 with those with a BMI $\geq$ 25. The MS level of fβhCG at 11-13^{+6} weeks was significantly (p<0.05) higher in women with a BMI $\geq$ 25. There was no significant difference for the other parameters between the two subgroups.

There was a significant positive correlation between the basal plate surface area (F= 10.30; r=0.20, p<0.001) and placental volume (F= 7.60; r=0.17, p< 0.01) at 11-13^{+6} weeks and subsequent fetal size. There was no significant correlation between MS fβhCG or PAPP-A at 11-13^{+6} weeks and mid-trimester AFP, uE3 and inhibin MS levels and fetal size.

10

3.2 LGA

The median birthweight was 4128g in the LGA subgroup (IQR 4000;4350) compared to 3289 g in the AGA subgroup (IQR 3121;3487, p<0.001). The concentration of MS PAPP-A at 11-13^{+6} weeks was significantly (p<0.05) higher in the serum of the women delivering an LGA neonate than in controls with a normal birthweight at term (Table 2). There was no significant difference for the ultrasound parameters in this subgroup. There was a significant positive correlation (F= 8.03; r=0.20, p<0.01) between MS PAPP-A concentration and increased birthweight at term (Figure 1), but no such relationship existed for MS fβhCG AFP, uE3 and inhibin.

3.4 SGA

The median birthweight was 2850g in the SGA subgroup (IQR 2800;2922) compared to 3462 g in the AGA control subgroup (IQR 3206;3632, p<0.001). There was no significant difference for the ultrasound and endocrinologic parameters between SGA and control pregnancies (Table 3). There was no significant correlation between MS-hormonal levels at 11-13^{+6} weeks and mid-trimester and SGA.

4. Discussion

Our results indicate a relationship between 2D measurements of the placentation area and volume, MS PAPP-A at 11-13^{+6} weeks of gestation and birthweight in uncomplicated singleton pregnancies that deliver at term. In otherwise uncomplicated pregnancies, presenting with LGA or SGA at term, 2D first-trimester ultrasound measurements of placentation are not related to abnormal fetal size and only MS PAPP-A are related to subsequent excessive fetal size.

There are well-documented associations between the levels of first and second trimester MS biomarkers and abnormal placental development in pregnancies subsequently complicated by pre-eclampsia and intrauterine growth restriction (IUGR). A longitudinal study has shown that in cases of IUGR, with or without accompanying pre-eclampsia, the placenta is already smaller at 12-18 weeks of gestation on ultrasound than in healthy controls [26]. In the most severe cases of deficient arterial conversion the intervillous circulation is abnormal from the beginning of the second trimester, resulting in pronounced ultrasonographic changes in placental texture [14,27,28], that are associated with IUGR, pre-eclampsia and high MS alpha-fetoprotein levels at 18-28 weeks [14]. In these pregnancies, there is a narrow implantation basis or basal plate diameter, increased thickness and patchy decrease in placental echogenicity secondary to the fetal plate being pushed up by jet-like blood streams from the spiral arteries [14]. We have previously shown that in pregnancies subsequently complicated by pre-eclampsia, the levels of MS PAPP-A are lower at the end of the first trimester and the basal plate surface area is smaller [24] reflecting indirectly the development of the definitive

267 placenta [24,25]. These findings support the concept that placental-related

268 complications of the second-half of gestation have their pathophysiological

269 origin in abnormal placentation and utero-placental development during the

270 first trimester of pregnancy [3].

271   In the present study, we have excluded pregnancies with an existing or

272 subsequent medical complications such as pre-eclampsia or gestational

273 diabetes and those that delivered pre or post-term. We observed that in the

274 subgroup presenting with a normal birthweight at term, there was a significant

275 positive correlation between birthweight and the basal plate surface area

276 ($p<0.001$) and PV ($p< 0.01$). In this subgroup, we also found that the MS level

277 of βhCG at 11-13^{+6} weeks was significantly higher ($p<0.05$) in women with a

278 BMI $\geq$ 25 than in women with a BMI < 25. First-trimester 3D placental volume

279 is closely associated with fetal and placental size [18] and hCG synthesis is

280 related to trophoblast proliferation and promotes development and growth of

281 the spiral arteries [29]. These findings highlight the pivotal interaction between

282 normal placentation, placental biosynthesis functions and normal fetal size,

283 and confirms that maternal BMI is a confounding factor that needs to be

284 adjusted for the first-trimester biochemical screening of trisomy 21.

285   In the LGA subgroup, we found that the MS PAPP-A at 11-13^{+6} weeks

286 of gestation was significantly higher ($p<0.05$) than in normal controls and was

287 positively correlated with birthweight at term. PAPP-A is mainly produced by

288 the villous trophoblast and during pregnancy its synthesis is up-regulated by

289 progesterone, which promotes the adhesion and proliferation potential of

290 trophoblastic cells [30]. It is also a key regulator of insulin-like growth factor

291 bioavailability essential for normal fetal development. This can explain why at

13

292 11-13^{+6} weeks of gestation, low MS levels of PAPP-A have been associated

293 with a higher risk of pre-eclampsia and poor fetal growth during the second

294 half of pregnancy [8-11,25,31]. Conversely, high MS PAPP-A levels as in the

295 present study have been associated with increased fetal size [21,32].

296 However, the sensitivity of MS PAPP-A at 11-13^{+6} weeks of gestation is too

297 low to be solely used as a screening method for the prediction of abnormal

298 birth weight and perinatal complications [8,9,11].

299   We found no difference in the ultrasound and biomarker parameters in

300 the present study between SGA and normal birthweight controls. It is possible

301 that our small sample size in the SGA group could explain the lack of

302 relationship between the parameters and fetal size in the SGA group. The

303 conflicting results from studies using first and second trimester 3D placental

304 volume measurements to predict fetal size in the third trimester [18,33] are

305 probably because of the difficulties with manual placental segmentation. In the

306 future innovative automatic segmentation approaches for 3D ultrasound may

307 be find placental measurements to be clinically applicable [34]. Variation in

308 placental volume is greater in the first trimester before 10 weeks i.e. before

309 the definitive placenta is fully formed [35], with a fundal or low placental

310 position being more difficult to assess than the fully anterior or posterior

311 position [33]. We have previously found that in pregnancies with a normal

312 outcome, there is no significant relationship between placental shape at 11-

313 13^{+6} weeks of gestation and birthweight or centile, suggesting that the

314 placental shape is not completely determined during the early phases of

315 placentation and is not directly related to fetal size during the first half of

316 pregnancy [24,25].

14

317   A distinct relationship exists between the uterine spiral arteries and the

318   fetal or placental lobules and the finding of a smaller basal plate surface area

319   at 11-13^{+6} weeks of gestation in pregnancies subsequently complicated by

320   pre-eclampsia [24]. This also suggests that ultrasound measurements of the

321   basal surface area reflects placentation indirectly and that this parameter is

322   less likely to be affected by the physiological morphological changes in the

323   placental structure between 8 and 12 weeks of gestation than placental

324   volume evaluated with 3D ultrasound.

325   **Conclusion**

326   In uncomplicated singleton pregnancies with a normal birthweight, 2D

327   measurements of placentation are related with fetal size but are not related to

328   subsequent excessive or slow fetal growth. LGA at birth is associated with

329   increased MS PAPP-A at 11-14 weeks of gestation supporting the association

330   between PAPP-A synthesis and early placental growth and development. The

331   clinical use of routine first trimester placental measurements in uncomplicated

332   pregnancies remains to be evaluated by large prospective cohorts.

333

334
335

336

337

338

References

1. Jauniaux E, Hempstock J, Greenwold N, Burton GJ. Trophoblastic oxidative stress in relation to temporal and regional differences in maternal placental blood flow in normal and abnormal early pregnancy. Am J Pathol 2003;162:115-125.

2. Burton GJ, Jauniaux E and Charnock-Jones DS The influence of the intrauterine environment on human placental development. International Journal of Developmental Biology. 2010;54:303-12.

3. Jauniaux E, Poston L, Burton GJ. Placental-related diseases of pregnancy: Involvement of oxidative stress and implications in human evolution. Hum Reprod Update. 2006;12:747-55.

4. Burton GJ, Sibley CP, Jauniaux E. Placental Anatomy and Physiology. In: Obstetrics: Normal and Problem Pregnancies. Sixth Edition. Edts: Gabbe SG, Niebyl JR, Simpson JL, Landon M, Galan H, Jauniaux E, Driscoll DA. Elsevier, Philadelphia. 3-22, 2012.

5. Jaddoe VW, de Jonge LL, Hofman A, Franco OH, Steegers EA, Gaillard R. First trimester fetal growth restriction and cardiovascular risk factors in school age children: population based cohort study. BMJ. 2014;348:g14.

6. Burkhardt T, Schäffer L, Schneider C, Zimmermann R, Kurmanavicius J. Reference values for the weight of freshly delivered term placentas and for placental weight-birth weight ratios. Eur J Obstet Gynecol Reprod Biol. 2006;128:248-52.

7. Forbes K, Westwood M. Maternal growth factor regulation of human placental development and fetal growth. J Endocrinol. 2010;207:1-16.

8. Giudice I, Benintende G, Di Nicolò AM, et al. Correlation of neonatal weight with maternal serum levels of pregnancy-associated plasma protein-A during the first trimester of pregnancy: a retrospective study. J Perinat Med. 2014. Leung TY, Sahota DS, Chan LW, Law LW, Fung TY, Leung TN, Lau TK. Prediction of birth weight by fetal crown-rump

376   length and maternal serum levels of pregnancy-associated plasma
377   protein-A in the first trimester. Ultrasound Obstet Gynecol. 2008;31:10-
378   4.

379   9. Goetzinger KR, Singla A, Gerkowicz S, Dicke JM, Gray DL, Odibo AO.
380   The efficiency of first-trimester serum analytes and maternal
381   characteristics in predicting fetal growth disorders. Am J Obstet
382   Gynecol. 2009;201:412.e1-6.

383   10. D'Antonio F, Rijo C, Thilaganathan B, Akolekar R, Khalil A,
384   Papageourgiou A, Bhide A. Association between first-trimester
385   maternal serum pregnancy-associated plasma protein-A and obstetric
386   complications. Prenat Diagn. 2013;33(9):839-47.

387   11. Nanda S, Akolekar R, Sodre D, Vaikousi E, Nicolaides KH. Maternal
388   serum adiponectin at 11-13 weeks of gestation in pregnancies
389   delivering small for gestation neonates. Fetal Diagn Ther. 2011;29:274-
390   9.

391   12. Nanda S, Akolekar R, Sarquis R, Mosconi AP, Nicolaides KH. Maternal
392   serum adiponectin at 11 to 13 weeks of gestation in the prediction of
393   macrosomia. Prenat Diagn. 2011;31:479-83.

394   13. Jauniaux E, Jurkovic D, Campbell S, Hustin J. Doppler ultrasound study
395   of the developing placental circulations: Correlation with anatomic
396   findings. Am J Obstet Gynecol 1992;166:585-7.

397   14. Jauniaux E, Ramsay B, Campbell S. Ultrasonographic investigation of
398   placental morphology and size during the second trimester of
399   pregnancy. Am J Obstet Gynecol 1994;170:130-7.

400   15. Proctor LK, Toal M, Keating S, et al. Placental size and the prediction of
401   severe early-onset intrauterine growth restriction in women with low
402   pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol.
403   2009;34:274-82.

404   16. Collins SL, Stevenson GN, Noble JA, Impey L. Rapid calculation of
405   standardized placental volume at 11 to 13 weeks and the prediction of
406   small for gestational age babies. Ultrasound Med Biol. 2013;39:253-60.

407   17. Effendi M, Demers S, Giguère Y, et al. Association between first-
408   trimester placental volume and birth weight. Placenta.2014;35:99-102.

409   18. Orzechowski K, Thomas D, McNamara CJ, Miller RC. Volumetric
410   assessment of longitudinal placental growth. Obstet Gynecol.
411   2014;123:164S.

412   19. de Almeida Pimenta EJ, Silva de Paula CF, Duarte Bonini Campos JA,
413   et al. Three-dimensional sonographic assessment of placental volume
414   and vascularization in pregnancies complicated by hypertensive
415   disorders. J Ultrasound Med. 2014;33:483-91.

416   20. Plasencia W, Akolekar R, Dagklis T, Veduta A, Nicolaides KH.
417   Placental volume at 11-13 weeks' gestation in the prediction of birth
418   weight percentile. Fetal Diagn Ther. 2011;30:23-8.

419   21. Schwartz N, Sammel MD, Leite R, Parry S. First-trimester placental
420   ultrasound and maternal serum markers as predictors of small-for-
421   gestational-age infants. Am J Obstet Gynecol. 2014. pii: S0002-
422   9378(14)00206-3.

423   22. Hata T, Tanaka H, Noguchi J, Hata K. Three-dimensional ultrasound
424   evaluation of the placenta. Placenta.2011:32:105-15.

425   23. Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS. New
426   intrauterine growth curves based on United States data. Pediatrics.
427   2010;125:e214-24.

428   24. Suri S, Muttukrishna S, Jauniaux E. 2D-ultrasound and endocrinologic
429   evaluation of placentation in early pregnancy and its relationship to
430   fetal birthweight in normal pregnancies and pre-eclampsia. Placenta.
431   2013;34:745-50.

432 25. Jauniaux E, Suri S, Muttukrishna S. Evaluation of the impact of
433   maternal smoking on ultrasound and endocrinological markers of first
434   trimester placentation Early Hum Dev. 2013;89:777-80.

435 26. Hafner E, Metzenbauer M, Höfinger D, et al. Comparison between
436   three-dimensional placental volume at 12 weeks and uterine artery
437   impedance/notching at 22 weeks in screening for pregnancy-induced
438   hypertension, pre-eclampsia and fetal growth restriction in a low-risk
439   population. Ultrasound Obstet Gynecol 2006;27:652-7.

440 27. Toal M, Chan C, Fallah S, et al. Usefulness of a placental profile in
441   high-risk pregnancies. Am J Obstet Gynecol 2007;196**:**363 e1-7.

442 28. Viero S, Chaddha V, Alkazaleh F, et al. Prognostic value of placental
443   ultrasound in pregnancies complicated by absent end-diastolic flow
444   velocity in the umbilical arteries. Placenta 2004;25**:**735-41.

445 29. Zygmunt M, Herr F, Keller-Schoenwetter S, et al. Characterization of
446   human chorionic gonadotropin as a novel angiogenic factor. J Clin
447   Endocrinol Metab. 2002;87:5290–6.

448 30. Wang J, Liu S, Qin HM, Zhao Y, Wang XQ, Yan Q. Pregnancy-
449   associated plasma protein A up-regulated by progesterone promotes
450   adhesion and proliferation of trophoblastic cells. Int J Clin Exp Pathol.
451   2014;7:1427-37.

452 31. Kalousová M, Muravská A, Zima T. Pregnancy-associated plasma
453   protein A (PAPP-A) and preeclampsia. Adv Clin Chem. 2014;63:169-
454   209.

455 32. Poon LC, Karagiannis G, Stratieva V, Syngelaki A, Nicolaides KH.
456   First-trimester prediction of macrosomia. Fetal Diagn Ther.
457   2011;29:139-47.

458 33. Hoopmann M, Schermuly S, Abele H, Zubke W, Kagan KO. First
459   trimester pregnancy volumes and subsequent small for gestational age
460   fetuses. Arch Gynecol Obstet. 2014;290:41-6.

461 34. Stevenson GN, Collins SL, Ding J, Impey L, Noble AD. 3-D Ultrasound
462 Segmentation of the Placenta Using the Random Walker Algorithm:
463 Reliability and Agreement, *Ultrasound Med. Biol.* Sep. 2015 in press.
464 35. Salafia CM, Yampolsky M, Shlakhter A, Mandel DH, Schwartz N.
465 Variety in placental shape: when does it originate? Placenta.
466 2012;33:164-70.
467

Table 1. Comparison (W test) of the birthweight, crown rump length (CRL), ultrasound

and endocrinological data in women with a booking BMI < 25 (n= 193) with those with a

BMI $\geq$ 25 (n= 66). BMI was measured at 8-10 weeks of gestation

Variables	BMI < 25		BMI $\geq$25		
	Median	LQ;UQ	Median	LQ;UQ	p
CRL (mm)	63	56;70	62	57;70	0.80
Birthweight (g)	3475	3226;3689	3454	3251;3622	0.89
Placental thickness (mm)	18.1	15.6;21.6	18.4	16.1;21.8	0.81
Basal plate surface (mm^2)	442	319;531	398	313;517	0.23
Placental volume (mm^3)	67.2	45.6;94.7	61.9	47.7;77.8	0.35
fβhCG (MoM)	0.98	0.69;1.42	1.20	0.76;1.84	<0.05
Inhibin A (MoM)	0.95	0.74;1.29	1.10	0.80;1.27	0.23
PAPP-A (MoM)	1.08	0.74;1.51	0.95	0.70;1.30	0.19

Data are presented as median and lower quartile (LQ); upper quartile (UQ).

Table 2. Comparison of the median for the ultrasound and endocrinological measurements of placental development in LGA neonates (birthweight >90th centile, n= 30) and controls (birthweight 10th-90th centile, n=90).

Variables	LGA		Controls		
	Median	LQ;UQ	Median	LQ;UQ	p
Placental thickness (mm)	18.2	15.2;21.7	17.9	15.3;22.0	0.91
Basal plate surface (mm^2)	446	366;522	453	346;556	0.36
Placental volume (mm^3)	63.4	47.7;87.1	68.4	49.9;87.5	0.71
fβhCG (MoM)	1.13	0.69;1.59	1.09	0.72;1.46	0.78
Inhibin A (MoM)	0.88	0.67;1.18	1.02	0.78;1.26	0.17
PAPP-A (MoM)	1.27	0.98;1.73	1.03	0.74;1.46	<0.05

Data are presented as median and lower quartile (LQ); upper quartile (UQ).

Table 3. Comparison of the median for the ultrasound and endocrinological measurements of placental development in SGA neonates (birthweight <10th centile, n= 17) and controls (birthweight 10th-90th centile, n=56).

Variables	SGA		Controls		
	Median	LQ;UQ	Median	LQ;UQ	p
Placental thickness (mm)	17.5	14.7;19.3	18.5	17.5;21.5	0.11
Basal plate surface (mm^2)	458	368;586	443	318;519	0.91
Placental volume (mm^3)	64.5	52.7;82.4	67.6	47.1;88.6	0.27
fβhCG (MoM)	1.09	0.91;1.58	1.11	0.75;1.58	0.87
Inhibin A (MoM)	0.98	0.80;1.08	1.09	0.78;1.37	0.45
PAPP-A (MoM)	1.15	0.91;1.26	1.08	0.74;1.49	0.91

Data are presented as median and lower quartile (LQ); upper quartile (UQ).

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

Figure 1 Legend

Scatter plot illustrating the relationship between first trimester maternal serum

PAPP-A Multiple of the Median (MoM) and birthweight in the Large for

Gestational Age group. The regression line is indicated in blue, the red and

the purple lines indicate the confidence intervals.

Supplementary Figure 1 Legend

Scatter plot illustrating the relationship between first trimester placental

surface area and birthweight for the whole cohort. The regression line is

indicated in blue, the red and the purple lines indicate the confidence

intervals.

Supplementary Figure 2 Legend

Scatter plot illustrating the relationship between first trimester placental 2D

volume and birthweight for the whole cohort. The regression line is indicated

in blue, the red and the purple lines indicate the confidence intervals.

Supplementary File

Supplementary File